C.B Dollaway, one of the maestro UFC fighters has been banned for two years by USADA for using banned performance enhancement banned substances.

The Officials from USADA (United States Anti-Doping Agency) announced the news of banning Dollaway for using banned stuff which comes under UFC’s anti-doping policy.

Dollaway, 35, tested positive for anastrozole, growth hormone releasing peptide 2 (GHRP-2 or pralmorelin), a metabolite of GHRP-2, and GHRP-6 as the result of an out-of-competition urine sample he provided on December 19, 2018. Anastrozole is a Specified Substance in the class of Hormone and Metabolic Modulators, while GHRP-2 and GHRP-6 are Specified Substances in the class of Peptide Hormones, Growth Factors, Related Substances and Mimetics.

“Dollaway also tested positive for clomiphene in an out-of-competition urine sample collected on February 9, 2019.”

Anastrozole is used to treat women suffering from Breast Cancer however, in men the same can be used to reduce the estrogen level produced in the body which also happens to be a side effect of using Steroids or Testosterone.

GHRP-6 on the other hand is a synthetically produced hormone which can be used to increase endurance along with other performance enhancing advantages.

Clomiphene has become a common drug found in numerous failed tests with past UFC athletes including Brock Lesnar and Jon Jones. Clomiphene is another drug typically used by women but can be used to spike testosterone production in men.

Dollaway was also busted for using an IV over the allowed limit by athletes competing in the UFC.

“Dollaway received an over-the-limit intravenous (IV) infusion on December 13, 2018,” USADA officials stated. “IV infusions and/or injections of more than 100 mL per 12-hour period are prohibited, except for those legitimately received in the course of hospital treatments, surgical procedures, or clinical diagnostic investigations.”

While Dollaway failed multiple tests over a period of time, USADA ultimately based his suspension on the date of the original failure, which is what kicked off his period of ineligibility.

“Dollaway’s two positive tests and use of an over-the-limit IV were treated as a single, first violation because, after a thorough investigation, it was determined that the positive tests were consistent with ingestion prior to January 11, 2019, the date he received notification of his first positive test,” USADA officials said. “Dollaway’s two-year period of ineligibility began on December 13, 2018.”

That means Dolloway will not be eligible to return to action until after Dec. 13, 2020.

Dolloway hasn’t competed since September 2018 when he suffered a TKO loss to Khalid Murtazaliev in Russia, which stopped his two-fight win streak. Now he will be forced to sit out until late 2020 when he’s allowed to compete again.

Abhinav Mallik
Author

A Journalist who has been working for B2B segment for almost half a decade. He has developed a knack of writing deliberate reports on indigenous market leaders across different sectors like health, fitness and sports goods manufacturing. He developed a discrete interest in covering business reports including business events, expos, and trade fairs.

Write A Comment

1 × three =

      SUBSCRIBE NEWS LETTER

By navigating our site, you agree to allow us to use cookies, in accordance with our Privacy Policy.